Beijing, China, Recently— Following the successful conclusion of the International Diabetes Academic Conference 2025 in Beijing, Gan & Lee Pharmaceuticals. (Stock Code: 603087.SH) welcomed an international delegation for a site visit and in-depth discussions. Over 50 leading diabetes Key Opinion Leaders (KOLs) from six countries gathered at the Gan & Lee’s headquarters to gain firsthand insight into its R&D and manufacturing facilities.

The delegation toured Gan & Lee’s R&D and production facilities, where they learned about the company’s innovation platforms, insulin manufacturing processes, and rigorous quality control systems.

Gan & Lee continues to advance its innovation pipeline, with a strong focus on next-generation therapies including the biweekly GLP-1 RA Bofanglutide (GZR18) and the once-weekly insulin GZR4. Several of these domestic programs are making significant strides in international multicenter clinical trials.

As the first Chinese insulin manufacturer to obtain EU GMP certification, Gan & Lee presented its fully integrated production system—from active pharmaceutical ingredient synthesis to drug formulation, pen assembly, and automated packaging. With its intelligent, large-scale manufacturing platform and robust quality standards, the company not only meets the strict regulatory demands of global markets, but also ensures a stable, long-term supply of diabetes medications. Visiting experts recognized Gan & Lee's world-leading research competencies and its well-established industrial platform in biopharmaceutical production.

The visit closely followed the international conference, which brought together experts from around the globe to discuss unmet clinical needs and the latest developments in diabetes care—shaping the future of therapeutic innovation.

“Gan & Lee Pharmaceuticals is deeply privileged to welcome this esteemed assembly of international experts,” said Liu Gai, Director of International Business at Gan & Lee Pharmaceuticals. “As a pioneer in China’s diabetes treatment landscape, we are deeply committed to providing high-quality products and improve human lives globally. Looking ahead, we will continue to foster global partnerships, promote access to affordable, high-quality diabetes treatments, and contribute Chinese expertise to improving health outcomes worldwide.”

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.